A 5-Question Quiz on Melanoma

Article

Are you up to date on the latest BRAF and MEK inhibitors used in melanoma? How about the most common location of metastasis in uveal melanoma? Answer these questions and more.

Question 1:

Answer and Question 2 on Next Page »

The correct answer is B. Doxorubicin

Question 2:

Answer and Question 3 on Next Page »

The correct answer is D. 2 cm

Question 3:

Answer and Question 4 on Next Page »

The correct answer is B. Crizotinib

Question 4:

Answer and Question 5 on Next Page »

The correct answer is C. Liver

Question 5:

Answer on Next Page »

The correct answer is A. Neural crest

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
2 experts in this video
Related Content
Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer

ONCOLOGY Staff
July 2nd 2025
Article

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
July 2nd 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article